Astellas Pharma is on track to purchase Ocata Therapeutics (formerly Advanced Cell Technology). This has stirred a lot of strong feelings amongst investors in Ocata. (Update, now almost 5 years later, the Ocata vision program is still not going full steam ahead at its new owner it seems). I’ve also been wondering what exactly is Astellas Pharma? Astellas is a giant compared to Ocata with reportedly $11 billion USD in revenue and $1.3 billion in profit just in the year 2013 alone. While Ocata …Read More
With more than 4,142 votes cast, the readers of this blog have chosen the top 12 finalists for the Stem Cell Person of the Year Award for 2014 from the 27 nominees. You can see the final vote tallies at left. The votes came from more than 50 countries with some interesting geographic patterns (I may do a post on that as a follow up). I’ve pasted the brief bios of the twelve finalists below at the end of this post. Now comes the …Read More
Here is a link to the Ocata website, marking the start of a new era for what was formerly Advanced Cell Technology or ACT. It’s been a big summer for stem cell biotech Advanced Cell Technology (ACT; stock ACTCD) as it continues what I would call a process of reinventing itself. What’s been happening? ACT recently did a notable 100:1 reverse split on its stock, opening it up to a whole new group of investors. The company has also settled some previously lingering litigation and …Read More
Before I did the #icebucketchallenge, I challenged the leader of Advanced Cell Technology (ACT), Dr. Bob Lanza, to do the Ice Bucket Challenge. He did it and leading up to it he provided a quite articulate message for context (see video below). Bob is one very cool guy even without ice water. The purpose of the Ice Bucket Challenge is to raise money for ALS research. Bob nominated ACT scientists Irina Klimanskaya, Shi-Jiang (John) Lu, and Erin Kimbrel to go next.